Citigroup Inc Aurinia Pharmaceuticals Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Citigroup Inc holds 759,269 shares of AUPH stock, worth $4.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

759,269

Previous 1,416,834 46.41%

Holding current value

$4.34 Million

Previous $12.7 Million 70.14%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$4.93 - $9.31 $3.24 Million - $6.12 Million	-657,565 Reduced 46.41%	759,269 $3.8 Million
Q4 2023 Feb 09, 2024	BUY	$7.13 - $9.49 $3.8 Million - $5.06 Million	532,884 Added 60.28%	1,416,834 $12.7 Million
Q3 2023 Nov 09, 2023	SELL	$7.77 - $12.27 $162,828 - $257,130	-20,956 Reduced 2.32%	883,950 $6.87 Million
Q2 2023 Aug 10, 2023	BUY	$8.96 - $11.69 $504,188 - $657,807	56,271 Added 6.63%	904,906 $8.76 Million
Q1 2023 May 11, 2023	SELL	$5.94 - $11.27 $6,343 - $12,036	-1,068 Reduced 0.13%	848,635 $9.3 Million

Q4 2022 Feb 09, 2023	SELL	$4.11 - $8.14 $4,015 - $7,952	-977 Reduced 0.11%	849,703 $3.67 Million
Q3 2022 Nov 10, 2022	SELL	$6.66 - $12.39 $73,639 - $136,996	-11,057 Reduced 1.28%	850,680 $6.4 Million
Q2 2022 Aug 10, 2022	BUY	$8.95 - $12.8 $853,140 - $1.22 Million	95,323 Added 12.44%	861,737 $8.66 Million
Q1 2022 May 12, 2022	SELL	$10.05 - $22.48 $17,899 - $40,036	-1,781 Reduced 0.23%	766,414 $9.49 Million
Q4 2021 Feb 10, 2022	BUY	$17.78 - $33.08 $13.5 Million - $25.1 Million	758,272 Added 7641.56%	768,195 $17.6 Million
Q3 2021 Nov 10, 2021	BUY	$10.93 - $23.55 $108,458 - $233,686	9,923 New	9,923 $220,000

Others Institutions Holding AUPH

# of Institutions

205

Shares Held

55.6M

Call Options Held

838K

Put Options Held

1.18M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $810M
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account